Intravitreal anti-VEGF use not tied to systemic adverse events
(HealthDay)—Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment is not associated with increased risk of systemic adverse events for patients with neovascular age-related macular degeneration, diabetic ...
Mar 26, 2018
0
2